The RVU Reversal: What Hospital Outperformance Actually Means for Your Independent Practice
For years, the conventional wisdom in orthopedic surgery held that independent practice owners were the productivity leaders. You built your own practice, controlled your schedule, and as a result you generated more work RVUs than your hospital-employed colleagues who spent half their time navigating system bureaucracy.
That benchmark just reversed.
Recent published compensation and productivity surveys show hospital and system-employed orthopedic surgeons now outperforming their independent counterparts on median work RVU output. The gap is not enormous, but it is consistent. And it is the first time in recent memory that the employed model has led on productivity.
Consider what that data says to someone thinking about buying your practice.
What Is Actually Driving the Shift
The drivers of the shift are structural. Hospital systems have invested heavily in scheduling infrastructure: OR time is protected, case coordinators manage patient flow, and referral networks route volume directly to their physicians. Independent practices, meanwhile, have been absorbing recent CMS reimbursement reductions on many procedure codes under changes to the Physician Fee Schedule, while also managing their own administrative overhead.
The result is a widening gap in usable clinical hours. An independent surgeon who spends 20% of her week on administrative tasks that a hospital-employed peer has offloaded to support staff generates fewer RVUs. The constraint is the infrastructure available to support clinical work. When you are running the business and practicing surgery simultaneously, something has to give.
This is an explanation of why the productivity gap has appeared, and why addressing it financially may matter more than it has in the past.
What Buyers Now Use as Their Benchmark
This is where the shift becomes a financial planning issue. Practice valuations in orthopedics are built on normalized EBITDA applied to a market multiple. The normalization step adjusts the practice's reported earnings for factors buyers assume won't persist post-sale, including the selling surgeon's compensation.
The standard normalization logic has always been: replace the owner's salary with a market rate for a comparable employed surgeon. If the market rate for a hospital-employed orthopedic surgeon at similar volume is $700K and you have been paying yourself $875K, the normalization adds back $175K to EBITDA.
Here is what is changing: buyers are increasingly using the hospital productivity benchmark to stress-test the revenue side of that normalization as well. If hospital-employed surgeons in a comparable market generate 10–15% more RVUs, and a buyer models the practice's revenue under a “normalized” surgeon who operates at that benchmark, the revenue assumption may come down even if the seller's current productivity is strong. The buyer is modeling what happens after the transaction, on the other side of closing.
Consider a surgeon with a practice generating $1.45M in normalized EBITDA. A 4x multiple values it at $5.8M. If a buyer's analyst runs a 10% productivity-adjusted revenue haircut on the forward model (representing the assumption that the replacing surgeon will be more productively limited without the seller's specific referral relationships and clinical reputation), the forward EBITDA drops to roughly $1.31M. At 4x, the practice is worth $5.24M. The RVU shift, unaddressed, has moved $560K out of this surgeon's exit outcome before a single term has been negotiated.
Many sophisticated buyers are now incorporating productivity benchmarks into their forward revenue models in this way.
The PE Calculus
Private equity firms in orthopedics use productivity benchmarks as part of their physician quality screening. The second wave of consolidation remains active, with significant deal activity reported through 2025 and into 2026 in many markets. A surgeon with an independent practice that outperforms the hospital benchmark on work RVUs is a more attractive acquisition target, because it signals that clinical volume will hold or grow post-transaction. PE investors pricing a deal assume some post-sale productivity drop as the seller transitions out of ownership responsibilities. A surgeon who is already outperforming the hospital benchmark provides a larger buffer.
A practice that has slipped below the hospital benchmark, even if the surgeon is exceptional by every clinical measure, introduces a revenue recovery assumption into the PE model that reduces the initial offer. The offer reflects a benchmark that moved. The practice's clinical quality is irrelevant to that adjustment.
Three Moves That Matter Now
Know your own RVU output. If you have not compared your annual work RVU generation against recent MGMA and AAOS benchmark data for your subspecialty and employment setting in the past 12 months, that number is now a gap in your financial plan. Your billing service and practice management system can produce this in 48 hours. You need the number before anyone else in a potential transaction does.
Audit the infrastructure gap. The productivity advantage hospital systems hold is almost entirely infrastructure-driven. Scheduling efficiency, case coordination, and referral process can all be improved in an independent practice. For illustration, if operational improvements produced an additional $125K–$150K of annual EBITDA, a 4x multiple would add roughly $500K–$600K in potential practice value, assuming buyer multiples and structures hold and clinical hours stay the same. If your administrative overhead ratio has never been benchmarked against specialty-adjusted MGMA standards, this is the quarter to do it.
Re-examine your exit timeline against the current data. If you are 3–5 years from a transaction, the RVU reversal adds urgency to the personal goodwill documentation, practice systematization, and buyer positioning work that should already be underway. A practice owner who runs this analysis and addresses the infrastructure gap now will reach the market at the moment of maximum competitive advantage. A practice owner who waits until the market adjusts fully will have missed it.
The Part That Doesn't Show Up in the Data
There is a reason you built an independent practice instead of accepting a hospital employment contract. You wanted to make clinical decisions for your patients without a system dashboard weighing in. You wanted to own what you built. You wanted the optionality that comes with controlling an asset.
None of that changes with the RVU reversal. Your practice's value is not only its productivity. It is the personal goodwill you have built with referring physicians, the operational know-how embedded in your team, and the reputation you have earned in your community. Those elements are real, they are documentable, and when properly structured in a sale, amounts attributable to goodwill may be eligible for capital gains treatment under current tax law, subject to IRS rules and individual circumstances. Tax consequences depend on your specific facts and current IRS guidance, so you should consult your CPA or tax attorney before relying on any tax characterization.
The RVU data is a diagnostic signal, not a verdict. The best surgeons I know run the same analysis on their practices that they run on their patients: current data, honest diagnosis, and a treatment plan calibrated to what is actually happening today.
Your practice may be the most productive asset in the market. Or it may have a gap worth closing in the next 18 months. The only way to know is to look.
Capably Yours,
Jared
DISCLAIMER
This article is for informational and educational purposes only and does not constitute investment, tax, or legal advice. It does not take into account the specific objectives, financial situation, or needs of any particular person. You should consult your own tax, legal, and investment professionals before acting on any information contained herein. Capable Wealth, a New York registered investment adviser, provides advisory services only where properly licensed or exempt from licensing.